Sitagliptin and metformin reduced HW/FL, hyperglycemia, hyperlipidemia and proteinuria in GK rats.

(a) Physical and plasmatic parameters were evaluated in the rats (n=10, each group). Representative photographs of rats and hearts for each group are also shown. BW, body weight; HW, heart weight, FL, femur length; Ch, cholesterol, TG, triglycerides; LDL and HDL, low- and high-density lipoproteins; NEFA, non-esterified fatty acid; S.B.P., systolic blood pressure. (b) Sitagliptin mitigated cardiac hypertrophy in GK rats. The LV posterior wall (LVPW) and inter-ventricular septum (IVS) thicknesses, LV diastolic (LVDD) and LV systolic (LVSD) diameters, LV mass index (LVMI), ejection fraction (EF) and the deceleration time were achieved in the rats myocardia (n=10, each g roup). Representative Echo-Doppler images for each group of rats are also shown (top). (c) Hematoxilin/Eosin staining of rat hearts with the corresponding semi-quantitative score of LVPW and IVS thicknesses. *p<0.05 and **p<0.01 vs. wistar. †p<0.05 and ††p<0.01 vs. GK rats.

(a) 本研究对各组大鼠（每组n=10）的生理及血浆参数开展了检测与评估，同时展示了各组大鼠及其心脏的代表性影像照片。其中BW为体重（body weight），HW为心脏重量（heart weight），FL为股骨长度（femur length），Ch为胆固醇（cholesterol），TG为甘油三酯（triglycerides），LDL与HDL分别为低密度脂蛋白（low-density lipoproteins）和高密度脂蛋白（high-density lipoproteins），NEFA为非酯化脂肪酸（non-esterified fatty acid），S.B.P.为收缩压（systolic blood pressure）。(b) 西格列汀（Sitagliptin）可缓解GK大鼠的心肌肥厚。本研究检测了各组大鼠心肌的左心室后壁（left ventricular posterior wall, LVPW）、室间隔（inter-ventricular septum, IVS）厚度，左心室舒张末期内径（LV diastolic diameter, LVDD）、左心室收缩末期内径（LV systolic diameter, LVSD），左心室质量指数（LV mass index, LVMI）、射血分数（ejection fraction, EF）以及心肌减速时间（每组n=10），同时展示了各组大鼠的代表性超声多普勒成像结果（上图）。(c) 对大鼠心脏组织进行苏木精-伊红（Hematoxilin/Eosin）染色，并给出了LVPW与IVS厚度的半定量评分结果。统计学差异标注如下：与Wistar大鼠相比，*p<0.05且**p<0.01；与GK大鼠相比，†p<0.05且††p<0.01。